Slingshot members are tracking this event:

Development of Varlilumab and Nivolumab (Opdivo) to Advance to Phase 2 Study - Open Enrollment to Begin Q2 of 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Additional Relevant Details A Phase 1/2 study of varlilumab and nivolumab (Opdivo) completed enrollment and from this Celldex and Bristol-Meyers Squibb have decided to advance the development to a Phase 2 study.  The study will include cohorts in advanced non-small cell lung cancer, colorectal cancer, ovarian cancer, head and neck squamous cell carcinoma, renal cell carcinoma and glioblastoma. Open enrollment begins second quarter of 2016. The companies are sharing development costs.
Additional Relevant Details "we are very excited for the Phase 2 portion of the trial, which is now open to enrollment across six different indications."
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 18, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Varlilumab, Nivolumab, Opdivo, Multiple Solid Tumors